1. Home
  2. CDXS vs DTIL Comparison

CDXS vs DTIL Comparison

Compare CDXS & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Codexis Inc.

CDXS

Codexis Inc.

HOLD

Current Price

$1.47

Market Cap

256.3M

Sector

Industrials

ML Signal

HOLD

Logo Precision BioSciences Inc.

DTIL

Precision BioSciences Inc.

HOLD

Current Price

$7.09

Market Cap

214.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDXS
DTIL
Founded
2002
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
256.3M
214.7M
IPO Year
2008
2019

Fundamental Metrics

Financial Performance
Metric
CDXS
DTIL
Price
$1.47
$7.09
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$45.00
AVG Volume (30 Days)
1.4M
436.7K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
43.82
N/A
EPS
N/A
N/A
Revenue
$138,590,000.00
$1,070,000,000.00
Revenue This Year
$7.73
N/A
Revenue Next Year
$14.24
N/A
P/E Ratio
N/A
N/A
Revenue Growth
32.30
N/A
52 Week Low
$0.96
$3.53
52 Week High
$3.87
$9.62

Technical Indicators

Market Signals
Indicator
CDXS
DTIL
Relative Strength Index (RSI) 28.27 39.50
Support Level $1.17 $6.30
Resistance Level $1.86 $7.96
Average True Range (ATR) 0.11 0.49
MACD -0.06 -0.15
Stochastic Oscillator 9.25 11.82

Price Performance

Historical Comparison
CDXS
DTIL

About CDXS Codexis Inc.

Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.

About DTIL Precision BioSciences Inc.

Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).

Share on Social Networks: